By contrast, surface markers of CSCs are favorable targets for diagnoses and may affect cancer treatment, such as CD133 for an aggressive subtype of GBM observed in younger patients with shorter survival periods (Jamal et al., 2012; Yan et al., 2011) and CD90 for high‐grade gliomas (He et al., 2012; Parry and Engh, 2012). This evidence concerns the gene THY1 and glioma.